Danish drugmaker Novo Nordisk said on Tuesday it has filed 14 new lawsuits in the United States against the sale of unapproved versions of semaglutide, the main ingredient in its popular weight-loss and diabetes drugs, Wegovy and Ozempic.
The new lawsuits target pharmacies and telehealth companies producing compounded versions of semaglutide “under the fake guise of personalization,” Novo said, without naming the companies.
Shares of major telehealth firm Hims & Hers HIMS.N extended losses to fall nearly 13% in afternoon trade. It had earlier reported weaker-than-expected quarterly revenue.
A Reuters search of legal filings found